Dosimetry and Uptake Patterns on 177 Lu-PSMA Scintigraphy Correlation with Gastro-Intestinal Adverse Events in mCRPC Treated Patients (EANM 2026) - Sep 29, 2026 - Abstract #EP-1006; P2 | "177Lu-PSMA-617 images were obtained during the first cycle using a hybrid imaging protocol: planar scintigraphy acquired at +4h, +24h, +48h, +72-96h, and +168h; and single SPECT/CT at +24h post-injection, respectively... This study provides the first estimates of GI absorbed doses from [177Lu]Lu-PSMA therapy. Correlation analysis between absorbed dose estimates, physician visual assessments, and reported GI adverse events are currently under evaluation."
Adverse events • Clinical • Castration-Resistant Prostate Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
Z. Ells 1; I. C. Azour 1; V. B. Ludwig 1; C. A. Meyer 1; L. M. Unterrainer 1, 2; P. G. Maliha 1; T. Grogan 1; J. Czernin 1; M. Dahlbom 1; J. Calais 1
|